- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AVALYN PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.08. | Avalyn Pharma Inc.: Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 | 1 | GlobeNewswire (USA) | ||
| 12.08. | Avalyn Pharma reports Q2 results | 2 | Seeking Alpha | ||
| 12.08. | Avalyn Pharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Avalyn Pharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Avalyn Pharma Inc.: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 269 | GlobeNewswire (Europe) | Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society... ► Artikel lesen | |
| 01.07. | Avalyn Pharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Klinischer Studienfortschritt beflügelt Avalyn Pharma Aktie | 2 | Investing.com Deutsch | ||
| 17.06. | Avalyn Pharma completes enrollment in pulmonary fibrosis trial | 1 | Investing.com | ||
| 17.06. | Avalyn Pharma Inc.: Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis | 625 | GlobeNewswire (Europe) | BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (Avalyn or the Company), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment... ► Artikel lesen | |
| 17.06. | Avalyn Pharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.06. | Avalyn Pharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.06. | Avalyn Pharma reports Q1 results | 4 | Seeking Alpha | ||
| 03.06. | Avalyn Pharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | Avalyn Pharma Inc.: Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights | 374 | GlobeNewswire (Europe) | On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable... ► Artikel lesen | |
| 26.05. | This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | 1 | Benzinga.com | ||
| 26.05. | Morgan Stanley startet Coverage für Avalyn Pharma mit "Overweight" und 84 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 26.05. | Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating | 2 | Investing.com | ||
| 25.05. | Jefferies stuft Avalyn Pharma nach Daten zu Lungenkrankheit mit "Buy" ein | 2 | Investing.com Deutsch | ||
| 25.05. | Jefferies initiates Avalyn Pharma stock with buy on lung disease data | 2 | Investing.com | ||
| 25.05. | Guggenheim stuft Avalyn Pharma mit "Kaufen" ein und sieht großes Potenzial bei Fibrose-Medikamenten | 5 | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,85 | +0,17 % | Klarheit über Biontech-Standort bis Ende September | MAINZ (dpa-AFX) - Biontech will bis Ende September über die Zukunft der von der Schließung bedrohten Produktionsstandorte in Deutschland und Singapur entscheiden. Dabei gehe es um das Ausloten möglicher... ► Artikel lesen | |
| AMGEN | 383,85 | +0,44 % | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| NOVAVAX | 8,930 | +0,34 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 193,14 | +0,49 % | Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Disease | WESTON (dpa-AFX) - Drug makers Biogen Inc. (BIIB) and Japan's Eisai Co., Ltd. (ESALY.PK, 4523.T, EII.SG) announced Thursday that the National Medical Products Administration or NMPA of China... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 738,20 | +0,34 % | Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector? | ||
| VIKING THERAPEUTICS | 28,900 | -0,17 % | Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. | ||
| INTELLIA THERAPEUTICS | 11,240 | +2,18 % | Cathie Wood's ARK sells Shopify stock, buys Intellia Therapeutics | ||
| TEMPUS AI | 53,48 | +0,09 % | Tempus AI gains as Cantor issues new Overweight on Data and applications segment | ||
| BIOCRYST PHARMACEUTICALS | 8,660 | -0,73 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 56,48 | -2,32 % | Ascendis Pharma: Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (Navepegritide) | COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with... ► Artikel lesen | |
| EXELIXIS | 51,10 | +1,13 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| SAREPTA THERAPEUTICS | 19,640 | -2,04 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,834 | -3,27 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,125 | -0,92 % | PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen |
Das Unternehmen AVALYN PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 35,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AVALYN PHARMA INC finden Sie auf Wallstreet Online.